BioSpace News Archive

Hillhurst Biopharmaceuticals, Inc. announced the completion of a financing that, together with non-dilutive sources, funds Phase 2a clinical studies in sickle cell disease and in a second clinical indication.

EpiVax, Inc. (“EpiVax”), an internationally recognized leader in the field of immunogenicity, today announced that Eisai Co. Ltd. (“Eisai”) has licensed EpiVax’s ISPRI toolkit for preclinical immunogenicity risk assessment of Eisai’s robust biologics pipeline.

Tonix Pharmaceuticals Holding Corp. announced that the Company has signed securities purchase agreements with certain healthcare-focused institutional investors that have agreed to provide up to $144 million in gross proceeds to Tonix through a registered direct offering that includes initial upfront funding of $30 million.

ulrich medical USA, the pioneer in expandable corpectomy devices and a market leader in spine technology, today announced FDA clearance for expanded indications of the Momentum and Momentum MIS Posterior Spinal Fixation Systems.

Volpara Health Technologies Ltd. (ASX: VHT), a global leader in software for the early detection and prevention of cancer, was featured in two peer reviewed studies published during this year’s Radiological Society of North America (RSNA) annual meeting.

WRQ Sciences and Superfluid Dx, Inc., announced the completion of an oversubscribed Series A financing led by WRQ Sciences.

TheracosBio today announced that BRENZAVVY® (bexagliflozin), an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, will be available to Independent Pharmacy Cooperative (IPC) members.

ResMed is conducting a voluntary global field action to update its guides for all masks with magnets to inform users about potential magnetic interference when magnets are near certain implants and medical devices in the body.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced the closing of the expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel® or EBVALLOTM).

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.